• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Research and Markets: Metastatic and Hormone Refractory Prostate Cancer

Posted on: Tuesday, 19 October 2004, 12:00 CDT

Research and Markets (http://www.researchandmarkets.com) has announced the addition of Stakeholder Insight: Metastatic And Hormone Refractory Prostate Cancer to their offering.

Prostate cancer is the most common male malignancy in Western countries. Increasing usage of screening and changes in treatment practice means companies will have to adapt to exploit the market. Wes Metastatic and HRPC Prostate Cancer Insight details physician opinion of currently available products and disease management practice and what they require in the future.

Scope:

-- Quantitative treatment data from over 440 physicians: 60 from Japan, France, Germany, Italy, Spain and the UK, and 80 from the US

-- Qualitative feedback on key findings and future trends in the treatment of prostate cancer and the management of disease and treatment side effects

-- A strong future focus on key issues, including the increasing use of third generation cytotoxics in HRPC and the implementation of screening in Europe

Highlights

-- Clinical trials have shown the lack of activity of estramustine in hormone refractory prostate cancer, but the drug is still commonly used because of the lack of alternatives. Recent trial results of estramustine in combination with Aventis Taxotere show much greater efficacy and usage of this combination is already significant.

-- In Japan the volume usage of hormonal drug therapy is far more common as the average age of the patient is well over 70 and so curative treatment is often contraindicated. We believe the high volume usage of hormonal therapies makes this an important country in which to market effective, low toxicity drugs.

Reasons to Purchase

-- Identify hot topics and key issues for practicing prostate cancer specialists the questions they really want answered

-- Identify hot topics and key issues for practicing prostate cancer specialists the questions they really want answered

-- Plan product development to fill prostate cancer market niches as defined by practicing physicians

CHAPTER 1 EXECUTIVE SUMMARY 3

CHAPTER 2 INTRODUCTION 25

The prostate 26

Prostate cancer 27

Histology 27

Etiology 28

Epidemiology 30

Incidence forecasts 32

Point prevelence forecasts 33

CHAPTER 3 SCREENING, DIAGNOSIS AND STAGING 34

Screening 34

Prostate cancer screening 34

Summary and comments 40

Diagnostic methods 41

Staging 42

Clincal staging 42

Gleason grade 45

Physician data 47

Screening 47

The effect of screening on presentation pattern 51

Diagnosis and staging tests 54

CHAPTER 4 TREATMENT OF METASTATIC DISEASE 59

Treatment options for metastatic prostate cancer 59

Surgery 59

Radiotherapy 62

Drug therapy 64

Summary 75

Lymph metastases 75

Distant metastases 76

Physician data 77

Refusing treatment 77

Surgery 79

Radiotherapy 86

Drug therapy 93

CHAPTER 5 TREATMENT OF HRPC 111

Definition of HRPC 111

Development of HRPC 111

Progression to HRPC 112

Prognosis of HRPC 113

Approved agents for HRPC 115

Estramustine 115

Mitoxantrone 119

Key investigational agents for HRPC 121

Taxol (paclitaxel) 121

Taxotere (docetaxel) 122

Taxol versus Taxotere 124

Navelbine (vinorelbine) 125

Ketaconazole 127

Estrogens 128

Physician data 130

Drug therapy for HRPC patients 130

Drug regimens for HRPC 138

The use of cytotoxics in the last five years 150

Key investigational drugs for HRPC 153

Atrasentan (ABT-627) 154

Thalomid (thalidomide) 157

Iressa (gefitinib) 159

YM598 161

Glivec (imatinib) 162

Conclusions 163

CHAPTER 6 SIDE EFFECTS AND SUPPORTIVE CARE 164

Loss of bone integrity and bone pain 164

Sexual function-related side effects including hot flashes 164

Loss of libido 164

Impotence/erectile dysfunction 168

Hot flashes 173

Discontinuation of treatment due to sex-related side effects 179

Incontinence and diarrhea 180

Urinary incontinence 180

Bowel incontinence 184

Diarrhea 186

Discontinuation of treatment due to the side effects 188

Breast-related side effects 189

Gynecomastia 189

Breast pain (and tenderness) 193

Discontinuation of treatment due to gynecomastia and breast pain 196

Psychological side effects 197

CHAPTER 7 SUPPORTING DATA 198

Duration of first-line drug therapy and progression factors 198

Second-line drug therapy 202

Third-line drug therapy 206

For more information visit http://www.researchandmarkets.com/reports/c7680

Source: Business Wire

More News in this Category